Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial.
Anticoagulant
Bioprosthetic valve
Bleeding
Cardiac surgery
Embolism
Journal
Cardiovascular drugs and therapy
ISSN: 1573-7241
Titre abrégé: Cardiovasc Drugs Ther
Pays: United States
ID NLM: 8712220
Informations de publication
Date de publication:
24 Jun 2024
24 Jun 2024
Historique:
accepted:
21
05
2024
medline:
24
6
2024
pubmed:
24
6
2024
entrez:
24
6
2024
Statut:
aheadofprint
Résumé
Anticoagulant therapy with vitamin K antagonists is recommended within 3 to 6 months after bioprosthetic valve replacement to prevent thromboembolic events. However, data regarding whether direct oral anticoagulants can be an alternative to warfarin in such patients are limited. The purpose of this study is to compare the efficacy and safety of edoxaban versus warfarin within 3 months after bioprosthetic valve replacement. The ENBALV trial is an investigator-initiated, phase 3, randomized, open-label, multicenter study. It involves patients aged 18 to 85 years undergoing bioprosthetic valve replacement at the aortic and/or mitral position. They are randomized 1:1 to receive either edoxaban or warfarin. Administration of edoxaban or warfarin is to be continued for 12 weeks after surgery. The primary outcome is the occurrence rate of stroke or systemic embolism at 12 weeks after surgery. The net clinical outcome is a composite of stroke, systemic embolism, or major bleeding, which is included in the secondary outcomes. The ENBALV trial demonstrates the efficacy and safety of edoxaban compared with warfarin in patients early after bioprosthetic valve replacement, including patients with sinus rhythm, which will bring a significant benefit to patients in clinical practice. Japan Registry of Clinical Trials (jRCT) 2051210209. 30 Mar 2022 https://jrct.niph.go.jp/latest-detail/jRCT2051210209 .
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Anticoagulant therapy with vitamin K antagonists is recommended within 3 to 6 months after bioprosthetic valve replacement to prevent thromboembolic events. However, data regarding whether direct oral anticoagulants can be an alternative to warfarin in such patients are limited. The purpose of this study is to compare the efficacy and safety of edoxaban versus warfarin within 3 months after bioprosthetic valve replacement.
METHODS
METHODS
The ENBALV trial is an investigator-initiated, phase 3, randomized, open-label, multicenter study. It involves patients aged 18 to 85 years undergoing bioprosthetic valve replacement at the aortic and/or mitral position. They are randomized 1:1 to receive either edoxaban or warfarin. Administration of edoxaban or warfarin is to be continued for 12 weeks after surgery. The primary outcome is the occurrence rate of stroke or systemic embolism at 12 weeks after surgery. The net clinical outcome is a composite of stroke, systemic embolism, or major bleeding, which is included in the secondary outcomes.
CONCLUSION
CONCLUSIONS
The ENBALV trial demonstrates the efficacy and safety of edoxaban compared with warfarin in patients early after bioprosthetic valve replacement, including patients with sinus rhythm, which will bring a significant benefit to patients in clinical practice.
TRIAL REGISTRATION
BACKGROUND
Japan Registry of Clinical Trials (jRCT) 2051210209. 30 Mar 2022 https://jrct.niph.go.jp/latest-detail/jRCT2051210209 .
Identifiants
pubmed: 38913220
doi: 10.1007/s10557-024-07585-x
pii: 10.1007/s10557-024-07585-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Head SJ, Çelik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J. 2017;38:2183–91.
doi: 10.1093/eurheartj/ehx141
pubmed: 28444168
Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA. 2012;308:2118–25.
doi: 10.1001/jama.2012.54506
pubmed: 23188028
Brennan JM, Edwards FH, Zhao Y, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the society of thoracic surgeons adult cardiac surgery national database. J Am Coll Cardiol. 2012;60:971–7.
doi: 10.1016/j.jacc.2012.05.029
pubmed: 22921973
Heras M, Chesebro JH, Fuster V, et al. High Risk of Thromboemboli Early After Bioprosthetic Cardiac Valve Replacement. J Am Coll Cardiol. 1995;25:1111–9.
doi: 10.1016/0735-1097(94)00563-6
pubmed: 7897124
Zhang H, Dong Y, Ao X, Fu B, Dong L; CLIATHVR (Chinese Low Intensity Anticoagulant Therapy After Heart Valve Replacement) multicenter clinical study team. Comparison of antithrombotic strategies in chinese patients in sinus rhythm after bioprosthetic mitral valve replacement: early outcomes from a multicenter registry in China. Cardiovasc Drugs Ther. 2021;35:1–10.
Russo A , Grigioni F, Avierinos JF, et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications.J Am Coll Cardiol. 2008;51:1203–11.
Izumi C, Eishi K, Ashihara K, et al. JCS/JSCS/JATS/JSVS 2020 guidelines on the management of valvular heart disease. Circ J. 2020;84:2037–119.
doi: 10.1253/circj.CJ-20-0135
pubmed: 32921646
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;2(143):e35–71.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2021. https://doi.org/10.1093/eurheartj/ehab395 .
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
doi: 10.1056/NEJMoa1310907
pubmed: 24251359
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
doi: 10.1056/NEJMoa1107039
pubmed: 21870978
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
doi: 10.1056/NEJMoa1009638
pubmed: 21830957
Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2015;132:624–32.
doi: 10.1161/CIRCULATIONAHA.114.014807
pubmed: 26106009
Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation. 2017;135:1273–5.
doi: 10.1161/CIRCULATIONAHA.116.026714
pubmed: 28209729
Guimarães PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 2019;42:568–71.
doi: 10.1002/clc.23178
pubmed: 30907005
pmcid: 6522998
Guimaraes HP, Lopes RD, de Barros e Silva PGM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020;383:2117–26.
Izumi C, Miyake M, Fujita T, et al. Antithrombotic therapy for patients with atrial fibrillation and bioprosthetic valves - real-world data from the multicenter, prospective. Observational BPV-AF Registry Circ J. 2022;86:440–8.
pubmed: 34719560
Suppah M, Kamal A, Saadoun R, et al. An evidence-based approach to anticoagulation therapy comparing direct oral anticoagulants and vitamin k antagonists in patients with atrial fibrillation and bioprosthetic valves: a systematic review, meta-analysis, and network meta-analysis. Am J Cardiol. 2023;206:132–50.
doi: 10.1016/j.amjcard.2023.07.141
pubmed: 37703679
Pasciolla S, Zizza LF, Le T, Wright K. Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements. Clin Drug Investig. 2020;40:839–45.
doi: 10.1007/s40261-020-00939-x
pubmed: 32607688
Shim CY, Seo J, Kim YJ, et al. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg. 2023;165:58–67.
doi: 10.1016/j.jtcvs.2021.01.127
pubmed: 33726903
Beller JP, Krebs ED, Hawkins RB, et al. Non-vitamin K oral anticoagulant use after cardiac surgery is rapidly increasing. JTCS. 2020;160:1222–31.
Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38:899–906.
pubmed: 28110293
Koretsune Y, Yamashita T, Akao M, et al. Baseline demographics and clinical characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry. Circ J. 2019;83:1538–45.
doi: 10.1253/circj.CJ-19-0094
pubmed: 31168044
Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016. BMJ Open. 2019;9: e026645. https://doi.org/10.1136/bmjopen-2018-026645 .
doi: 10.1136/bmjopen-2018-026645
pubmed: 31005934
pmcid: 6500377
Chang WT, Ho CH, Chang CL, Cheng BC, Wu NC, Chen ZC. Influence of warfarin on cardiac and cerebrovascular events following bioprosthetic aortic valve replacement: a nationwide cohort study. J Thorac Cardiovasc Surg. 2020;159:1730–9.
doi: 10.1016/j.jtcvs.2019.04.096
pubmed: 31208804
Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–24.
doi: 10.1056/NEJMoa1509233
pubmed: 26436963
Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120–9.
doi: 10.1056/NEJMoa1911425
pubmed: 31733180